Less than 30% of persons worldwide that are afflicted with the congenital bleeding disorder, hemophilia A, receive treatment. Without treatment, hemophilia A is a lethal disorder resulting in death prior to adulthood. The mission of Expression Therapeutics is to develop novel therapies that will dramatically improve the lives of people with hemophilia A around the world. Our goal is to implement two comprehensive strategies. The first is to develop a lower cost recombinant protein product that can be provided to those patients in need and the second is to develop a cure through gene therapy.